Several recently published articles, including two papers in the Journal of Infectious Diseases, look at whether PrEP efficacy is more likely to be driven by systemic drug levels in peripheral blood mononuclear cells (PBMCs) rather than by drug levels in genital and rectal mucosal tissue.
The difference is important and not just academic.
This is because drug levels in immune cells including in PBMCs are not affected by either sex or gender or exposure risk.
Both papers support even simpler event-based dosing (sometimes called on-demand dosing) as an option for everyone – and including for cisgender women, transgender men and non-binary people, and when the exposure risk is related to injecting drugs.
Read the full news story here.
Source : HIV i-Base
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.